| Background: Endometrial carcinoma is one of the three most malignant tumors of female genital tracts,accounting for about 7% of the total number of female cancer.And it is 20% to 30% of female genital tract tumors.In recent years,incidence of endometrial carcinoma in the world is on the rise,and the mechanism is not clear,which targets of effective prevention and treatment of endometrial cancer has not been found.Endometrial cancer is divided into two types.Type I endometrial carcinoma accounts for 70% to 80%,which malignant is low and which occurrence due to long-term estrogen stimulation.The high risk factor of endometrial carcinoma are endocrine disorder and metabolic disorder,which involve obesity,diabetes,high blood pressure,insulin resistance and polycystic ovary syndrome and so on,which is also known as estrogen-dependent endometrial carcinoma.The morbidity of typeⅡendometrial carcinoma has nothing to do with estrogen,obesity or diabetes,which malignant is high.Transient receptor potential(transient receptor potential,TRP)channel is found in recent years,which are protein of nonselective cationchannels and exist in the cell membrane and intracellular organelles me-mbrane.TRPV1 is widely distributed in the human body,which is calledthe capsaicin receptor and because it can be activated by capsaicin.TRPV1 play an important role in many physiological functions,and is also associated with some pathological changes,for instance inflammation and tumor.The current research indicates that TRPV1 may improve and pr-event metabolic disorders,which includ the high risk factors of estrogen-dependent endometrial carcinoma,and it related to the growth and progr-ession of some cancer tissue.Animal experiments confirmed that TRPV1 can be expressed in endometrial glandular epithelium,and can be up-regulated under the regulation of estrogen.TRPV1 is involved in physiological and pathological process of many tumor,however,the expression of TRPV1 in human endometrial carcinoma have not been reported yet.Objective: Analyzing the expression of TRPV1 in endometrial carcinoma and the relationship between the clinicopathological characteristics of EC,by testing the expression level of TRPV1 in endometrial carcinoma tissues and cancer cells,in order to provide new ideas and new targets for the clinical diagnosis and treatment of endometrial carcinoma.Methods:1 73 endometrial carcinoma wax blocks were from the Second Hospital of Hebei Medical University between 2009-11-2 and 2015-8-31 in recent five years in the second hospital of Hebei medical university,including type I endometrial carcinoma 34 cases(average age 53.38±8.68),staging by the international union of gynecology and obstetrics(FIGO,2009)surgical-pathologic staging criteria: stage I 29 cases,stage III 5 cases.type II endometrial carcinoma 39 cases(average age 58.41±8.76),including 24 cases of clear cell carcinoma,12 cases of serous carcinoma and 3 cases poorly differentiated endometrial adenocarcinoma.The control groups including 10cases(average age 53.38±8.68)normal proliferation phase endometrium from whole hysterectomy specimens for Cervical squamous epithelial high-level lesions or squamous cell carcinoma,10 cases endometrial hyperplasia with no atypical cells(average age 37.60±8.96),endometrial hyperplasia accompaning atypical cells 10 cases(average age40.8±8.39).2 The distribution and expression of TRPV1 is measured by immunohistochemical SP method in different types of endometrium diseased tissue,and then analyses its role in the process of endometrial carcinoma and its relationship with clinical-pathological features of estrogen-dependent endometrial carcinoma.It is considered as positive that Immunohistochemical staining emerges light yellow to tan particles in cell cytoplasm.Specific decision criteria: scoring according to the degree of tinting: no tinter scoring 0point;Light yellow,slightly higher than the background scoring 1 point;Tan,significantly higher than the background scoring 2 points;Strong dyeing,with brown scoring 3 points.At the same time according to the positive cell percentage scoring: < 5% scoring 0 point;6% ~ 25% 1 point;26% ~ 50% 2points;51% ~ 75% three points;> 75% 4 points.It is divided into four levels after two scoring added: 0 ~ 1 point judging as negative(-),> 2 points are all positive,of which > 2 points are positive(+),3 ~ 4 points medium positive(++),more than 5 points strong positive(+ + +).3 cultivate human endometrial carcinoma cell line ISHIKAWA and HEC-1A(recipient in Peking university people′hospital of department of gynaecology laboratory),The expressions of estrogen receptor ER is high in the former,while is low in the latter.Cell protein were extracted in logarithmic phase and then TRPV1 were analyzed by Western blot.4 Statistical method: Datas were statistically analyzed by SPSS19.0software package.Measurement data was expressed by mean ± standard deviation,and enumeration data was expressed by n %(N/N).The relationship between the two groups was analyzed by chi-square analysis.If P<0.05,it is believed statistically significant.Results:1 General information type I endometrial carcinoma: 29 patients with stage I endometrial carcinoma,including the Ia stage of 23 cases and the Ib period 6 cases.Stage III 5 cases,including 2 cases stage IIIa,IIIb period 1 case and stage IIIc 2patients.No matter which stage it was,muscular infiltration degree less than1/2 25 cases and 9 cases were greater than or equal to 1/2.Histological grade:class I 16 cases,18 cases class II.39 patients were type II endometrial carcinoma.2 Conventional HE morphological observations:34 cases type I endometrial carcinoma tissues were glandularis or fluffy glandular structure,performing crowded,complexed branching structure.Some cases accompanied squamous differentiation,infection and clear nuclear atypia.12 cases serous carcinoma were characterized by complex nipple and/or glandular structure,accompanied by significant nuclear atypia and polymorphism.In 24 cases clear cell carcinoma tubecystic,papillary or solid structure are visible,which form by polygon or hobnail cells with focal high-level nuclear atypia.The nuclear atypical of 3 cases poorly differentiated endometrial adenocarcinoma tissue is not clear,but the adenoid structure is lost in most of the cancer tissue,presenting a solid sheet.3 Immunohistochemical results TRPV1 was expresseed in cell cytoplasm and cell membrane.In normal proliferation phase of endometrium,the expression of TRPV1 was strong in glandular epithelium.The positive rate of TRPV1 was 100% in glandular epithelium in 10 cases endometrial hyperplasia with no atypical cells and endometrial hyperplasia accompanied atypical cells.In 73 cases endometrial carcinoma tissues,the positive expression rate of TRPV1 is 43.8%(32/73).In type I endometrial carcinoma positive expression rate of TRPV1 is 73.5%(25/34),including 9 cases of negative expression,12 cases of weakly positive,positive 9 cases and strong positive 4 cases and further analysis show that the positive expression of TRPV1 has no significant relationship between type I endometrial carcinoma clinicopathological characteristics,which involve age,clinical pathologic staging,histological grading,muscular invasion depth,etc.In type II endometrial carcinoma the positive expression rate of TRPV1 was only 15.4%(6/39),including weakly positive expression 6cases and 33 cases negative expression.4 Western blot TRPV1 was expressed in the endometrial cancer cells ISHIKAWA,while it wasn’t expressed in HEC-1A.Conclusion:1 TRPV1 in normal endometrium and endometrial carcinoma tissues were expressed,while in endometrial carcinoma tissue the positive expression rate significantly reduced.2 The positive expression rate of TRPV1 in type I endometrial carcinoma was significantly higher than that of in type II endometrial carcinoma.3 TRPV1 was expressed in the endometrial cancer cells ISHIKAWA,while it wasn’t detected in HEC-1A. |
PDF Full Text Request